A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Phase I Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of GB18 Following Single Subcutaneous Injection in Healthy Adult Participants
Latest Information Update: 27 Nov 2025
At a glance
- Drugs Monoclonal antibodies (Primary)
- Indications Cachexia
- Focus Adverse reactions; First in man
- Sponsors Shenzhen Kexing Pharmaceutical
Most Recent Events
- 27 Nov 2025 New trial record